Approval · Notice of Compliance 25044 · 2021
COSENTYX: Notice of Compliance 25044
Issued January 20, 2021
A Notice of Compliance is Health Canada’s approval of a drug submission: a new drug, a new use or form, or a change to an approved one. The product itself is in the Drug Product Database, with its current status.
- Notice number
- 25044
- Date
- January 20, 2021
- Company
- Novartis Pharmaceuticals Canada Inc.Montreal, Quebec, Canada
- Product type
- Biologic
- Submission
- Supplement to a New Drug Submission (SNDS), supplement
- Submission class
- Other
- Reason
- New indication: plaque psoriasis pediatric patients. cosentyx is indicated for the treatment of severe plaque psoriasis in pediatric patients 12 to less tha 18 years of age who are candidates for systemic therapy or phototherapy and who have a body weight >50 kg
Products in this notice
| Brand | DIN | Status today |
|---|---|---|
| COSENTYX | Not yet assigned | — |
Medicinal ingredients
- SECUKINUMAB 150 MG per ML
- SECUKINUMAB 150 MG per VIAL